NCT07113964View on ClinicalTrials.gov

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

March 30, 2029

Conditions
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
Interventions
DRUG

QL1706 + olaparib

"QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies.~Other Names: Iparomlimab and Tuvonralimab Injection Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor with biologic activity in ovarian cancer as well as other solid tumors..~Other Names: NA"

Trial Locations (1)

210000

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER